PHILADELPHIA and VANCOUVER, British Columbia — February 17, 2026 — Leads & Copy — BriaCell Therapeutics Corp. reports its pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor in patients with metastatic breast cancer continues without modifications, following a positive recommendation from the independent Data Safety Monitoring Board (DSMB).
The DSMB identified no safety concerns after reviewing safety data from the Bria-ABC study (NCT06072612). This marks the fifth consecutive positive recommendation from the DSMB, supporting the favorable safety profile observed to date.
The FDA granted Fast Track designation to BriaCell’s ongoing Phase 3 study, reflecting the significant unmet medical need in metastatic breast cancer.
According to Dr. William V. Williams, President and Chief Executive Officer of BriaCell, the DSMB’s ongoing confirmation of the safety profile of the Bria-IMT regimen is encouraging.
BriaCell remains focused on advancing this program for patients with limited treatment options and looks forward to providing additional clinical updates as the study progresses.
BriaCell is a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care.
Source: BriaCell Therapeutics Corp.
